Download the Case Study to learn more.
Prodrugs are designed to address challenges related to the physicochemical properties of drugs, such as solubility, absorption and stability. This case study highlights the successful application of Syngene’s SynVent Integrated Drug Discovery platform to develop a prodrug for a parent compound in Phase 3 clinical development for epilepsy. By integrating medicinal chemistry and ADME expertise, they achieved a remarkable 2,500-fold improvement in solubility using innovative phosphate-based prodrugs. With rapid in vivo conversion and exceptional stability, this breakthrough offers a game-changing solution for treating epilepsy, ensuring efficient drug delivery and enhanced patient outcomes.
Offered Free by: Syngene
See All Resources from: Syngene
